Menu
Recruiting NCT06394674

High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

Phase II Interventional Non-Small Cell Lung Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Furmonertinib.
Who it may be relevant to
Registry conditions: Non-Small Cell Lung Cancer. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Prospective, Randomized, Phase ll Clinical Trial of Single-agent Treatment With Different Doses of Sulfamethoxazole Furmonertinib in Patients With Advanced, Metastatic Lung Adenocarcinoma Who Have Progressed After First- or Second-line Treatment With EGFR-TKl Osimertinib

Overview

This is a prospective, randomised, uncontrolled phase II clinical trial planned to include 84 subjects with metastatic lung adenocarcinoma that had progressed after first- or second-line treatment with Osmertinib, who were randomly assigned to trial group 1 and trial group 2, and were given Furmonertinib 160 mg and 240 mg once/day, orally, respectively, with efficacy evaluated every 6 weeks until disease progression, intolerable toxic side effects, or Subjects voluntarily withdrew informed consent.

Interventions

  • Drug Furmonertinib
    Drug: Furmonertinib

Primary outcome measures

  • Objective Response Rate(ORR) [Time frame: Analysis will occur when PFS maturity is observed at approximately 12 months from the first patient begin study treatment]
Secondary outcome measures (3)
  • Progression-free survival (PFS) [Time frame: The primary analysis of Progression-free survival (PFS) based on investigator assessment will occur when PFS maturity is observed at approximately 12 months after the first patient begin study treatment]
  • Disease Control Rate (DCR) [Time frame: Analysis will occur when PFS maturity is observed at approximately 12 months from the first patient begin study treatment]
  • Duration of Response (DoR) [Time frame: Duration of Response analysis will occur when Progression-free survival (PFS) maturity is observed at approximately 12 months from the first patient begin study treatment]

Eligibility criteria

Inclusion criteria

  • Histologically or cytologically confirmed metastatic lung adenocarcinoma
  • Progression of imaging-confirmed extracranial lesions after first- or second-line treatment with Osimertinib
  • Previous genetic testing for a definite EGFR-sensitive mutation and imaging-confirmed extracranial lesion progression after first-line treatment with Osimertinib; or previous genetic testing for a definite T790M mutation and imaging-confirmed extracranial lesion progression after second-line treatment with Osimertinib.
  • Pre-existing clinical benefit after treatment with Osimertinib, including CR, PR, SD (duration >6 months);
  • Patients with at least 1 measurable lesion according to the criteria for evaluating the efficacy of solid tumors (RECIST 1.1)
  • Normal functioning of major organs
  • Pre-menopausal women of childbearing potential with a negative serum or urine pregnancy test within 7 days prior to the first dose of the drug
  • Subjects volunteered and signed a written informed consent form.

Exclusion criteria

  • Previous chemotherapy or immunotherapy
  • Patients with non-lung adenocarcinoma, including squamous lung cancer or mixed histological types
  • Progression of imaging-confirmed extracranial lesions after prior Osimertinib treatment with accessible treatment options after genetic testing
  • Patients with symptomatic brain metastases, meningeal metastases or spinal cord compression
  • Any unrecovered CTCAE > grade 1 toxicity reaction following prior Osimertinib treatment at the start of study drug therapy
  • Other malignant tumors within 5 years or history of other malignant tumours; except effectively controlled basal cell carcinoma of the skin, carcinoma in situ of the uterine cervix, ductal carcinoma in situ of the breast, papillary carcinoma of the thyroid, superficial bladder tumors, etc.
  • History of interstitial pneumonia with previous diagnosis
  • Other circumstances that, in the judgement of the investigator, make them unsuitable for inclusion in the study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Changhai Hospital — Shanghai

Identifiers

NCT: NCT06394674 · CHEC2023-155

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗